Ashland pharmaceuticals viatel™ bioresorbable polymers

Ashland webinar – long-acting injectables: microsphere design, development and scale-up using Chroniject* with viatel™ lactide/glycolide polymers


view on demand

Long-acting injectable (LAI) drug products continue to gain importance as pharmaceutical developers seek to improve patient compliance, optimize therapeutic outcomes, and reduce dosing frequency. However, designing and scaling injectable microsphere formulations with predictable, tunable release profiles presents significant formulation and manufacturing challenges.

This joint webinar addresses those challenges by combining Ashland’s expertise in viatel™ lactide/glycolide-based bioresorbable polymer chemistry with Oakwood Labs' Chroniject* microsphere-based technology platform. Together, our presenters will explore how polymer selection, chemistry control and process parameters influence drug loading, release duration, particle size, encapsulation efficiency and scalability under cGMP conditions.
 
This 90-minute session will highlight practical insights into:

  • understanding how viatel™ bioresorbable polymer chemistry and critical quality attributes enable tunable release profiles in LAI formulations
  • Iearning how Chroniject* microsphere-based technology addresses formulation development and scale-up challenges
  • exploring strategies for coupling microsphere technology with bioresorbable polymers to deliver small molecules and peptides with controlled release
  • gaining insight into cGMP manufacturing considerations for sterile injectable microsphere products

Register for the webinar replay today to gain understandings of formulation development, scale-up strategies and real-world case studies for microsphere-based LAI products for a range of therapeutic applications.

presenter information:

Patrick Duffy, Ph.D.
Ashland Senior Team Leader, R&D

Dr. Patrick Duffy is the R&D Team Leader for the viatel™ bioresorbable polymer portfolio at Ashland and is responsible for all research and development activities related to this product line. He supports customers in the development of extended-release parenteral drug delivery formulations, medical devices, tissue engineering scaffolds, and cosmetics. He holds a B.Eng., M.Sc., and Ph.D. from University College Dublin and joined Ashland in 2018 following the Vornia Ltd. acquisition.

™ Trademark, Ashland or its subsidiaries, registered in various countries 
* Trademark owned by a third party

Rachel Minrovic
Oakwood Labs Manager, Senior Formulation Engineer

Rachel Minrovic is a Senior Engineer at Oakwood Labs, focusing on development and production of microsphere products and advancements in microsphere process technology, and her work has culminated in several patent filings on behalf of Oakwood. She is project manager of multiple projects involving the encapsulation and scale up of various active pharmaceutical ingredients (API) into biodegradable polymeric microspheres. These injectable microspheres, for both human and animal use, can extend the efficacy of APIs for as long as one week and up to one year in vivo. Rachel has a bachelor’s degree in chemical engineering from the University of Dayton, where she performed research in developing cell-based in vitro silver nanoparticle pharmacokinetic profiles in efforts to bridge the in vitro/in vivo gap.

 

viatel™ bioresorbable polymers clear syringe

register for webinar replay

Fill out the form to view or download our recent webinar.

By checking the subscribe box and submitting this form, I agree to my email address being stored and used to receive promotional emails from Ashland, and I acknowledge that I have read and understand the Ashland privacy policy.